In vitro megakaryocyte production and platelet biogenesis: state of the art.
In vitro megakaryocyte production and platelet biogenesis: state of the art.
复制标题
DOI：
10.1016/j.tmrv.2009.09.003
复制
发表时间：
2010-01
影响因子：
4.5
通讯作者：
Sun, Sijie
中科院分区：
文献类型：
--
作者：
Reems, Jo-Anna;Pineault, Nicolas;Sun, Sijie
The exciting and extraordinary capabilities of stem cells to proliferate and differentiate into numerous cell types not only offers promises for changing how diseases are treated, but may also impact how transfusion medicine is practiced in the future. The possibility of growing platelets in the laboratory to some day supplement and/or replace standard platelet products has clear advantages for blood bank centers and patients. Due to the high utilization of platelets by patients undergoing chemotherapy or receiving stem cell transplants, platelet transfusion has steadily increased over the past decades. This trend is likely to continue as the number of adult and pediatric patients receiving stem cell transplants is also continuously rising. As a result of increased demand coupled with the short shelf-life of platelet concentrates, providing platelets to patients can stretch the resources of most blood centers, drive donor recruitment efforts, and on occasion platelet shortages can compromise the care of thrombocytopenic patients. The purpose of this article is to review current scientific progress to develop in vitro strategies to manufacture platelets, with an emphasis on efforts to produce functional platelets in quantities that would be required for clinical transfusion. There are a number of publications indicating that human platelets can be obtained in vitro from the controlled differentiation of hematopoietic stem cells. However, the hemostatic quality of such manufactured platelets has not been confirmed and current technologies are inadequate to ensure satisfactory expansion and platelet biogenesis on an industrial scale. Nonetheless, these studies provide proof-of-principle that developing in vitro strategies to manufacture platelets is feasible and also provide a foundation for developing more sophisticated approaches to achieve this goal.
登录
查看更多内容
影响因子：
20.1
作者：
Bergmeier, W;Piffath, CL;Wagner, DD
通讯作者：
Wagner, DD
影响因子：
3.2
作者：
Drachman, JG
通讯作者：
Drachman, JG
影响因子：
2.6
作者：
Fukushima-Shintani, Mari;Suzuki, Ken-ichi;Kawasaki, Tomihisa
通讯作者：
Kawasaki, Tomihisa
影响因子：
2.6
作者：
Feng, Y;Zhang, L;Han, ZC
通讯作者：
Han, ZC
影响因子：
7.8
作者：
Clarke, Murray C H;Savill, John;Jones, David B;Noble, Brendon S;Brown, Simon B
通讯作者：
Brown, Simon B